Research
Hormonal
GLP-1 receptor agonists and SGLT2 inhibitors are effective pharmacological treatments for T2DM and obesity that target shared pathophysiological mechanisms like inflammation and insulin resistance.
If lifestyle changes are insufficient, ask your doctor about GLP-1 agonists or SGLT2 inhibitors. These drugs help manage blood sugar and weight by targeting hormonal pathways, offering an advantage over older medications that may cause weight gain.
GoodSupportsHIGH confidence
This review critically explores the mechanistic connections between obesity and T2DM, with a focus on recent advances in pharmacological therapies—such as GLP-1 receptor agonists, SGLT2 inhibitors, and dual GIP/GLP-1 receptor agonists
Why this rating
Cited as recent advances with promising efficacy in the review.
Source
Endocrine and Metabolic Mechanisms Linking Obesity to Type 2 Diabetes: Implications for Targeted Therapy
Salvatore Allocca et al. · Healthcare · 2025
DOI 10.3390/healthcare13121437
narrative_reviewCited 16×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lifestyle modifications, specifically calorie-restricted diets combined with moderate-intensity aerobic and resistance exercise, are first-line interventions that can induce Type 2 Diabetes remission and improve insulin sensitivity.Good
- Bariatric surgery is a highly effective therapeutic option for individuals with severe obesity (BMI ≥40 or ≥35 with comorbidities) that induces T2DM remission through metabolic changes beyond simple restriction.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →